Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2013-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2015512388-A |
titleOfInvention |
Combination therapy |
abstract |
The present invention relates to a MEK inhibitor compound 6- (4-bromo-2-fluorophenylamino) -7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid (2-hydroxyethyoxy) -amide or A pharmaceutical combination comprising a pharmaceutically acceptable salt and an IGF1R inhibitor antibody A, a pharmaceutical composition comprising such a combination, a therapeutically effective amount of such combination is administered to a subject in need thereof To a method for treating cancer, and the use of such a combination for the treatment of cancer. |
priorityDate |
2012-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |